Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib

  • Authors:
    • Yuh-Min Chen
    • Wen-Chien Fan
    • Pei-Chun Tseng
    • Chun-Ming Tsai
    • Teh‑Ying Chou
    • Chieh‑Hung Wu
    • Kun-Ta Chou
    • Yu-Chin Lee
    • Reury‑Perng Perng
    • Jacqueline Whang-Peng
  • View Affiliations

  • Published online on: December 23, 2011     https://doi.org/10.3892/ol.2011.534
  • Pages: 713-717
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tumor epidermal growth factor receptor (EGFR) mutation analysis is significant for making treatment decisions for metastatic pulmonary adenocarcinoma. However, less than half of patients have adequate tumor samples for mutation analysis. Patients with adenocarcinoma of the lungs who were due to receive erlotinib treatment were included in the present study. Tumor EGFR mutation status was analyzed using DNA sequencing. Plasma specimens from the patients were collected prior to erlotinib treatment. The plasma-free DNA EGFR mutation status was analyzed using the PCR clamp method. A total of 54 consecutive patients were included in the study. The plasma‑free DNA EGFR mutation status of the 54 patients was analyzed. Only 30 patients had adequate tumor samples for EGFR analysis, including 15 with activating mutations (exon 19 deletions or L858R). EGFR-activating mutations were detected in the plasma-free DNA in 25 of 54 patients. The response rate was 86.7 and 33.3% in patients with and without tumor activating mutations, respectively (p=0.002). The response rate was 68 and 31% based on the patients' plasma-free DNA EGFR mutation status, respectively (p=0.013). No significant difference in progression‑free survival (PFS) was observed between patients with and without EGFR-activating mutations, according to data from tumor tissue or plasma-free DNA analysis, although the median PFS time was longer for those patients with EGFR-activating mutations in plasma samples. Plasma EGFR mutation analysis is useful for adenocarcinoma patients who have no or inadequate tumor samples available for EGFR examination. Patients with plasma EGFR-activating mutations had an improved response rate and a statistically insignificant longer PFS.
View Figures
View References

Related Articles

Journal Cover

March 2012
Volume 3 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen Y, Fan W, Tseng P, Tsai C, Chou TY, Wu CH, Chou K, Lee Y, Perng RP, Whang-Peng J, Whang-Peng J, et al: Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. Oncol Lett 3: 713-717, 2012.
APA
Chen, Y., Fan, W., Tseng, P., Tsai, C., Chou, T., Wu, C. ... Whang-Peng, J. (2012). Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib. Oncology Letters, 3, 713-717. https://doi.org/10.3892/ol.2011.534
MLA
Chen, Y., Fan, W., Tseng, P., Tsai, C., Chou, T., Wu, C., Chou, K., Lee, Y., Perng, R., Whang-Peng, J."Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib". Oncology Letters 3.3 (2012): 713-717.
Chicago
Chen, Y., Fan, W., Tseng, P., Tsai, C., Chou, T., Wu, C., Chou, K., Lee, Y., Perng, R., Whang-Peng, J."Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib". Oncology Letters 3, no. 3 (2012): 713-717. https://doi.org/10.3892/ol.2011.534